Cargando…

Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines

(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in...

Descripción completa

Detalles Bibliográficos
Autores principales: Niebel, Dennis, Wenzel, Joerg, Wilsmann-Theis, Dagmar, Ziob, Jana, Wilhelmi, Jasmin, Braegelmann, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544472/
https://www.ncbi.nlm.nih.gov/pubmed/34698094
http://dx.doi.org/10.3390/dermatopathology8040049
_version_ 1784589824961806336
author Niebel, Dennis
Wenzel, Joerg
Wilsmann-Theis, Dagmar
Ziob, Jana
Wilhelmi, Jasmin
Braegelmann, Christine
author_facet Niebel, Dennis
Wenzel, Joerg
Wilsmann-Theis, Dagmar
Ziob, Jana
Wilhelmi, Jasmin
Braegelmann, Christine
author_sort Niebel, Dennis
collection PubMed
description (1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms.
format Online
Article
Text
id pubmed-8544472
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85444722021-10-26 Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines Niebel, Dennis Wenzel, Joerg Wilsmann-Theis, Dagmar Ziob, Jana Wilhelmi, Jasmin Braegelmann, Christine Dermatopathology (Basel) Article (1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms. MDPI 2021-09-27 /pmc/articles/PMC8544472/ /pubmed/34698094 http://dx.doi.org/10.3390/dermatopathology8040049 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Niebel, Dennis
Wenzel, Joerg
Wilsmann-Theis, Dagmar
Ziob, Jana
Wilhelmi, Jasmin
Braegelmann, Christine
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title_full Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title_fullStr Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title_full_unstemmed Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title_short Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
title_sort single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following covid-19 vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544472/
https://www.ncbi.nlm.nih.gov/pubmed/34698094
http://dx.doi.org/10.3390/dermatopathology8040049
work_keys_str_mv AT niebeldennis singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines
AT wenzeljoerg singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines
AT wilsmanntheisdagmar singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines
AT ziobjana singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines
AT wilhelmijasmin singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines
AT braegelmannchristine singlecenterclinicopathologicalcasestudyof19patientswithcutaneousadversereactionsfollowingcovid19vaccines